Episode notes
This week, we have two interviews. We chat with Step Pharma CEO, Andy Parker, and also have a conversation with Re-Vana CEO, Michael O’Rourke.
Ocular therapeutics
Re-Vana Therapeutics and Boehringer Ingelheim recently announced a $1bn+ deal to develop long-acting ophthalmic therapies.
Re-Vana Therapeutics is a privately held, US and UK based developer of ocular therapeutics and innovative ocular drug delivery technologies which spun out of Queens University Belfast, Northern Ireland.
Terms of the deal include up to three development programmes per year leading to a potential total deal value exceeding $1bn contingent on milestone achievements. The agreement gr ...
Keywords
biotechbiotechnologycancerophthalmologyeyesRe-Vana TherapeuticsStep Pharma